Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2965-2973

  Hauser, Andrea ^a,b   Mugenyi, Kizito ^c   Kabasinguzi, Rose ^c   Bluethgen, Kerstin ^b   Kuecherer, Claudia ^b   Harms, Gundel ^a   Kunz, Andrea ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Gesellschaft für Technische Zusammenarbeit mbH   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE;

ACCURACY; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STRUCTURAL GENE; UGANDA; VERTICAL TRANSMISSION; VIRUS MUTATION; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67649969553     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01672-08     Document Type: Article

References (37)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Arrivé, E., M. L. Newell, D. K. Ekouevi, M. L. Chaix, R. Thiebaut, B. Masquelier, V. Leroy, P. V. Perre, C. Rouzioux, F. Dabis, and the Ghent Group on HIV in Women and Children. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36:1009-1021.
3. Basson, A. E., M. Ntsala, N. Martinson, E. Tlale, G. E. Corrigan, X. Shao, G. Gray, J. McIntyre, A. Puren, and L. Morris. 2008. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J. Acquir. Immune Defic. Syndr. 49:538-543.
4. Charpentier, C., D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78:4234-4247.
5. Church, J. D., S. E. Hudelson, L. A. Guay, S. Chen, D. R. Hoover, N. Parkin, S. A. Fiscus, F. Mmiro, P. Musoke, N. Kumwenda, J. B. Jackson, T. E. Taha, and S. H. Eshleman. 2007. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res. Hum. Retrovir. 23:764-768.
6. Church, J. D., W. I. Towler, D. R. Hoover, S. E. Hudelson, N. Kumwenda, T. E. Taha, J. R. Eshleman, and S. H. Eshleman. 2008. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants. AIDS Res. Hum. Retrovir. 24:595-605.
7. Dao, H., L. M. Mofenson, R. Ekpini, C. F. Gilks, M. Barnhart, O. Bolu, and N. Shaffer. 2007. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource. Am. J. Obstet. Gynecol. 197:S42-S55.
8. DelRio-LaFreniere, S. A., and R. C. McGlennen. 2001. Simultaneous allele-specific amplification: a strategy using modified primer-template mismatches for SNP detection-application to prothrombin 20210A (factor II) and factor V Leiden (1691A) gene mutations. Mol. Diagn. 6:201-209.
9. De Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. Snoeck, E. J. van Rensburg, A. M. Wensing, D. A. van de Vijver, C. A. Boucher, R. Camacho, and A. M. Vandamme. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2:3797-3800.
10. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. Glenn Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957.
11. Eshleman, S. H., L. A. Guay, A. Mwatha, S. P. Cunningham, E. R. Brown, P. Musoke, F. Mmiro, and J. B. Jackson. 2004. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res. Hum. Retrovir. 20:595-599.
12. Eshleman, S. H., D. R. Hoover, S. Chen, S. E. Hudelson, L. A. Guay, A. Mwatha, S. A. Fiscus, F. Mmiro, P. Musoke, J. B. Jackson, N. Kumwenda, and T. Taha. 2005. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19:2167-2169.
13. Flys, T. S., S. Chen, D. C. Jones, D. R. Hoover, J. D. Church, S. A. Fiscus, A. Mwatha, L. A. Guay, F. Mmiro, P. Musoke, N. Kumwenda, T. E. Taha, J. B. Jackson, and S. H. Eshleman. 2006. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune. Defic. Syndr. 42:610-613.
14. Flys, T. S., D. Donnell, A. Mwatha, C. Nakabiito, P. Musoke, F Mmiro, J. B. Jackson, L. A. Guay, and S. H. Eshleman. 2007. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J. Infect. Dis. 195:711-715.
15. Gale, C. V., D. L. Yirrell, E. Campbell, L. Van der Paal, H. Grosskurth, and P. Kaleebu. 2006. Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda. AIDS Res. Hum. Retrovir. 22:985-992.
16. Guay, L. A., P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, M. Deseyve, L. Emel, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, K. Dransfield, D. Bray, F. Mmiro, and J. B. Jackson. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
17. Halvas, E. K., G. M. Aldrovandi, P. Balfe, I. A. Beck, V. F. Boltz, J. M. Coffin, L. M. Frenkel, J. D. Hazelwood, V. A. Johnson, M. Kearney, A. Kovacs, D. R. Kuritzkes, K. J. Metzner, D. V. Nissley, M. Nowicki, S. Palmer, R. Ziermann, R. Y. Zhao, C. L. Jennings, J. Bremer, D. Brambilla, and J. W. Mellors. 2006. Blinded multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614.
18. Johnson, J. A., J. F. Li, L. Morris, N. Martinson, G. Gray, J. McIntyre, and W. Heneine. 2005. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16-23.
19. Johnson, J. A., J. F. Li, X. Wei, J. Lipscomb, D. Bennett, A. Brant, M. E. Cong, T. Spira, R. W. Shafer, and W. Heneine. 2007. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2:e638.
20. Johnson, J. A., J. F. Li, X. Wei, J. Lipscomb, D. Irlbeck, C. Craig, A. Smith, D. E. Bennett, M. Monsour, P. Sandstrom, E. R. Lanier, and W. Heneine. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 5:e158.
21. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, M. Lallemant, and the Perinatal HIV Prevention Trial Group. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
22. Lecossier, D., N. S. Shulman, L. Morand-Joubert, R. W. Shafer, V. Joly, A. R. Zolopa, F. Clavel, and A. J. Hance. 2005. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J. Acquir. Immune Defic. Syndr. 38:37-42.
23. Lockman, S., R. L. Shapiro, L. M. Smeaton, C. Wester, I. Thior, L. Stevens, F. Chand, J. Makhema, C. Moffat, A. Asmelash, P. Ndase, P. Arimi, E. van Widenfelt, L. Mazhani, V. Novitsky, S. Lagakos, and M. Essex. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356:135-147.
24. Loubser, S., P. Balfe, G. Sherman, S. Hammer, L. Kuhn, and L. Morris. 2006. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20:995-1002.
25. Maga, G., M. Amacker, N. Ruel, U. Hübscher, and S. Spadari. 1997. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274:738-747.
26. Metzner, K. J., P. Rauch, H. Walter, C. Boesecke, B. Zöllner, H. Jessen, K. Schewe, S. Fenske, H. Gellermann, and H. J. Stellbrink. 2005. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19:1819-1825.
27. Metzner, K. J., S. G. Giulieri, S. A. Knoepfel, P. Rauch, P. Burgisser, S. Yerly, H. F. Günthard, and M. Cavassini. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48:239-247.
28. Palmer, S., V. Boltz, F. Maldarelli, M. Kearney, E. K. Halvas, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2006. Selection and persistence of non-nucleosid reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710.
29. Palmer, S., V. Boltz, N. Martinson, F. Maldarelli, G. Gray, J. McIntyre, J. Mellors, L. Morris, and J. Coffin. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. USA 103:7094-7099.
30. Paredes, R., V. C. Marconi, T. B. Campbell, and D. R. Kuritzkes. 2007. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J. Virol. Methods 146:136-146.
31. Pillay, V., J. Ledwaba, G. Hunt, M. Rakgotho, B. Singh, L. Makubalo, D. E. Bennett, A. Puren, and L. Morris. 2008. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir. Ther. 13(Suppl. 2):101-107.
32. Rayfield, M. A., R. G. Downing, J. Baggs, D. J. Hu, D. Pieniazek, C. C. Luo, B. Biryahwaho, R. A. Otten, S. D. Sempala, and T. J. Dondero. 1998. A molecular epidemiologic survey of HIV in Uganda. AIDS 12:521-527.
33. Rowley, C. F., C. L. Boutwell, S. Lockman, and M. Essex. 2008. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J. Virol. Methods 149:69-75.
34. Simen, B. B., J. F. Simons, K. H. Hullsiek, R. M. Novak, R. D. Macarthur, J. D. Baxter, C. Huang, C. Lubeski, G. S. Turenchalk, M. S. Braverman, B. Desany, J. M. Rothberg, M. Egholm, M. J. Kozal, and the Terry Beirn Community Programs for Clinical Research on AIDS. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701.
35. Stringer, J. S., M. Sinkala, V. Chapman, E. P. Acosta, G. M. Aldrovandi, V. Mudenda, J. P. Stout, R. L. Goldenberg, R. Kumwenda, and S. H. Vermund. 2003. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 17:659-665.
36. UNAIDS/W.H.O. 2007. AIDS epidemic update: December 2007. World Health Organization, Geneva, Switzerland.
37. Walter, H., B. Schmidt, K. Korn, A. M. Vandamme, T. Harrer, and K. Uberla. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13:71-80.